ANAPTYSBIO, INC ANAB

Latest FY: 2025 Healthcare Biotechnology
Market Price $58.44
Market Cap $1.63B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑157.0% YoY
$234.60M
3-Yr CAGR: 183.6%
Net Income ↑90.9% YoY
-$13.23M
Net Margin: -5.6%
Free Cash Flow ↑114.5% YoY
$19.61M
FCF Yield: 1.20%
EPS (Diluted) ↑91.0% YoY
$-0.46
Basic: $-0.46
Return on Equity Efficiency
-35.6%
ROA: -277.9%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (ANAB)

All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
  • FY 2021: Revenue YoY (-15.8%) is identical to Gross Profit YoY (-15.8%). Verify the underlying Revenue and Gross Profit values for FY 2021 and FY 2020.
  • FY 2022: Revenue YoY (-83.7%) is identical to Gross Profit YoY (-83.7%). Verify the underlying Revenue and Gross Profit values for FY 2022 and FY 2021.
  • FY 2023: Revenue YoY (+66.8%) is identical to Gross Profit YoY (+66.8%). Verify the underlying Revenue and Gross Profit values for FY 2023 and FY 2022.
  • FY 2024: Revenue YoY (+432.0%) is identical to Gross Profit YoY (+432.0%). Verify the underlying Revenue and Gross Profit values for FY 2024 and FY 2023.
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $16.7M $16.2M $-4.3M $-1.62 $-9.0M $-9.1M
FY 2017 $10.0M -40.1% $8.2M $-30.1M -606.0% $-1.52 +6.2% $-19.4M $-19.7M -117.3%
FY 2018 $5.0M -50.0% $3.3M $-61.7M -105.0% $-2.50 -64.5% $-48.5M $-49.6M -151.3%
FY 2019 $8.0M +60.0% $7.0M $-97.3M -57.9% $-3.60 -44.0% $-69.5M $-70.3M -41.9%
FY 2020 $75.0M +837.5% $75.0M $-19.9M +79.5% $-0.73 +79.7% $-14.2M $-14.7M +79.1%
FY 2021 $63.2M -15.8% $63.2M $-57.8M -190.0% $-2.11 -189.0% $-45.9M $-47.3M -221.1%
FY 2022 $10.3M -83.7% $10.3M $-128.7M -122.7% $-4.57 -116.6% $-73.6M $-74.0M -56.4%
FY 2023 $17.2M +66.8% $17.2M $-163.6M -27.1% $-6.08 -33.0% $-120.8M $-121.6M -64.4%
FY 2024 $91.3M +432.0% $91.3M $-145.2M +11.2% $-5.12 +15.8% $-135.3M $-135.7M -11.6%
FY 2025 $234.6M +157.0% $98.6M $-13.2M +90.9% $-0.46 +91.0% $19.7M $19.6M +114.5%
$

Valuation

Market Price $58.44
Market Cap $1.63B
Enterprise Value N/A
P/E Ratio N/A
P/B Ratio 45.70
FCF Yield 1.20%
Dividend Yield N/A
Shares Outstanding 29,100,900
%

Profitability & Margins

Gross Margin 42.04%
Operating Margin 20.42%
Net Margin -5.64%
Return on Equity (ROE) -35.56%
Return on Assets (ROA) -277.87%
Asset Turnover 49.27x
Revenue 3-Yr CAGR 183.58%
🛡️

Financial Health & Liquidity

Current Ratio 0.15
Cash Ratio 7.29
Debt / Equity N/A
Debt / Assets N/A
Cash & Equivalents $238.20M
Total Debt N/A
Book Value / Share $1.28
💧

Cash Flow Efficiency

Operating Cash Flow $19.70M
Capital Expenditures (CapEx) $87.00K
Free Cash Flow $19.61M
OCF / Revenue 8.40%
FCF / Revenue 8.36%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $-0.46
EPS (Basic) $-0.46
Dividends / Share N/A
Book Value / Share $1.28
EPS YoY Growth 91.02%
🏛️

Balance Sheet (FY 2025)

Total Assets $4.76M
Total Liabilities $32.67M
Stockholders' Equity $37.21M
Current Assets $4.76M
Current Liabilities $32.67M